![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 29, 22300-22304, July 21, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, April 17, 2000
The Raf-1 kinase plays a key role in relaying
proliferation signals elicited by mitogens or oncogenes. Raf-1 is
regulated by complex and incompletely understood mechanisms including
phosphorylation. A number of studies have indicated that
phosphorylation of serines 259 and 621 can inhibit the Raf-1 kinase. We
show that both serines are hypophosphorylated during early mitogenic
stimulation and that hypophosphorylation correlates with peak Raf-1
activation. Concentrations of okadaic acid that selectively inhibit
protein phosphatase 2A (PP2A) induce phosphorylation of these residues and prevent maximal activation of the Raf-1 kinase. This effect is
mediated via phosphorylation of serine 259. The PP2A core heterodimer forms complexes with Raf-1 in vivo and in
vitro. These data identify PP2A as a positive regulator of Raf-1
activation and are the first indication that PP2A may support the
activation of an associated kinase.
The Raf-1 kinase is an important intermediate in the transduction
of proliferative signals, and its activation may be a key event in the
development of a wide range of tumors (1). Activated Raf-1 can regulate
the mitogen-activated protein kinase network by phosphorylating and
activating MEK1; within the
mitogen-activated protein kinase cascade, Raf interacts physically with
MEK-1 via its kinase domain and with GTP-loaded Ras via its N terminus
(2). Activated Ras is the best studied activator of Raf-1. It binds to
Raf-1 with high affinity and mediates its translocation from the
cytosol to the plasma membrane, where activation takes place (3, 4).
Artificial tethering of Raf-1 to the cell membrane results in partial
activation, which can be further enhanced by mitogenic stimulation,
suggesting that at the cell membrane Raf-1 is exposed to both
constitutive and mitogen-regulated activators (5-8).
Mitogenic stimulation of cells typically induces hyperphosphorylation
of Raf-1 and a retardation of its migration on SDS gels. This
hyperphosphorylation correlates with the down-regulation of Raf-1
kinase activity (9, 10) and may be implemented by a negative feedback
mechanism depending on MEK activity (10, 11). Serines 43, 621, and 259 are phosphorylated in resting fibroblasts, albeit to different degrees
(12). Phosphorylation of all three residues has been implicated in the
negative regulation of Raf-1. Phosphorylation of serine 43 interferes
with Ras binding and consequently with Ras-mediated activation (3).
Phosphorylated serine 259 and serine 621 represent binding sites for
14-3-3 adaptor proteins (13, 14), whose function in Raf-1 activation is
controversial. While bivalent binding to Ser259 and
Ser621 has been suggested to maintain Raf-1 in an inactive
conformation (15, 16), reversible association with 14-3-3 facilitates
Ras-dependent activation in vivo and in
vitro (17). In particular, binding to the Ser(P)621
site appears to be necessary for kinase activity (16, 18), a finding
that contrasts with the studies indicating that phosphorylation of this
site by PKA in vitro is inhibitory (19). Therefore, the
significance of Ser621 phosphorylation is still in
question. Its investigation is hampered by the fact that
Ser621 is essential for the catalytic function of Raf-1 and
cannot be replaced by other amino acids without loss of kinase activity (19, 20). Serine 259 can be phosphorylated by protein kinase B, another
Ras effector activated in parallel with Raf, and this phosphorylation
correlates with the down-regulation of kinase activity (21). Consistent
with an inhibitory role of Ser(P)259, mutation of this
residue moderately activates the Raf-1 kinase in cultured cells (16,
22); the corresponding point mutants display a gain of function
phenotype in Drosophila (15, 20). Taken together, these data
raise the possibility that dephosphorylation of negative regulatory
residues plays a role in Raf-1 activation.
Protein phosphatase 2A (PP2A) is a major form of serine/threonine
phosphatase involved in the regulation of signal transduction, growth,
and development (23). This class of enzymes consists of a heterotrimer
that exists in multiple forms. The core components of all trimeric
forms are the 36-kDa catalytic subunit (PP2AC) and the 65-kDa
regulatory subunit (A subunit, PR65). This core heterodimer is
ubiquitous, and it forms complexes with "variable" subunits of
cellular origin (some of which are expressed in a tissue- and/or
development-restricted manner) as well as with transforming viral
antigens (24-26). Association with variable subunits of cellular and
viral origin occurs via the N-terminal leucine-rich repeats of PR65
(27) and confers distinct properties to the enzyme (28). Recently, PP2A
has been shown to form a complex with
Ca2+/calmodulin-dependent protein kinase IV
(29) as well as with PAK1, PAK3, and p70 S6 kinase (30). The isolated
catalytic subunit can associate with casein kinase 2 Cell Culture, Transfection, and Growth Factor
Stimulation--
BAC-1.2F5 cells (32) were cultured in Dulbecco's
modified Eagle's medium supplemented with 10% fetal calf serum and
0.63 nM purified mouse recombinant mitogen
colony-stimulating factor-1 (CSF-1) or 15% L-cell conditioned medium
(33) as a source of murine CSF-1. COS-1 and COS-7 cells were grown in
RPMI 1640 or Dulbecco's modified Eagle's medium supplemented with
glutamine and 10% fetal calf serum. COS cells were transfected by
electroporation (0.5-1 × 107 cells/cuvette, 240 V,
960 microfarads, 10 µg of plasmid DNA). The plasmids used were the
pCMV5 vector, pCMV.HAcat Monoclonal Antibody Production--
N-terminal
His6-tagged human PP2AC was expressed in the bacterial
strain M15[pREP4], and the fusion polypeptide was purified by
Ni2+-nitrilotriacetic acid chromatography (Qiagen).
Balb/c × CBA F1 mice (~3 months old) were immunized by
subcutaneous injection with 100 µg of bacterially expressed PP2AC
fusion protein emulsified with an equal volume of Titremax Gold (CytRx
Corp.). The immunization was repeated four times at three monthly
intervals, and then the mice rested for 6 months. A further 100 µg of
fusion protein in phosphate-buffered saline plus 0.1% SDS was injected
intraperitoneally at 6 and 3 days prior to sacrifice. Hybridoma lines
were then established by fusing splenocytes from the immunized animal
with the myeloma line Sp2/0-Ag14 by polyethylene glycol treatment and conventional procedures. Cell lines were screened for antibody production by a modified dot blot procedure using the bacterially expressed fusion protein (34) and cloned three times before tissue
culture fluid containing the monoclonal antibody was harvested. Clone
F2.8F5 was typed as an IgG2K species using Isotype strips (Roche
Molecular Biochemicals) and confirmed as specific for PP2AC by Western
blot analysis using total cell lysates. Using deletion mutants of PP2Ac
(35), the epitope has been mapped close to the C-terminal end of PP2AC.
Cell Lysis, Immunoprecipitation, and Western Blotting--
Cells
were lysed in solubilization buffer (10 mM Tris-Cl, 50 mM NaCl, 1% Triton X-100, 30 mM sodium
pyrophosphate, 100 µM Na3VO4, 1 mM phenylmethylsulfonyl fluoride). Insoluble material was
removed by centrifugation (15,000 rpm, 30 min, 4 °C).
Immunoprecipitation was performed exactly as described previously (36).
A rabbit polyclonal antiserum raised against a carboxyl-terminal
peptide of v-raf (SP63; CTLTTSPRLPVF) was used to
immunoprecipitate Raf-1 molecules. A mouse monoclonal antibody against
PP2AC (F2 8F5) was used to immunoprecipitate PP2A. HA-tagged PR65 Assay of Kinase and Phosphatase Activity--
Raf-1 kinase
activity was measured as the ability of immunoisolated Raf-1 to
phosphorylate recombinant, catalytically inactive MEK-1
(MEK Protein Purification and Pull-down Assays--
The GST-Raf-1
fusions used in this study have been previously described (42). The
proteins were expressed by standard techniques in the baculovirus
Sf9 cell system and purified as described previously (43) with
the exception that 1% Triton X-100 was added before binding to
GST-agarose. For pull-down assays, 100-200 ng of GST-Raf-1 fusion
proteins were incubated with either 1 mg of whole cell lysates or 200 ng of purified heterodimer, PR65 In Vivo Labeling of Cells and Phosphotryptic Peptide
Mapping--
32P-Labeling of cells was performed as
described previously (36). Cell lysis and immunoprecipitation of Raf-1
proteins were performed as described above. 32P-Labeled
proteins were resolved by 7.5% SDS-PAGE, extracted from the gels, and
subjected to digestion with sequencing grade trypsin (Promega)
according to the manufacturer's instructions prior to phosphopeptide
mapping. Tryptic peptides were separated in the first dimension by
electrophoresis using pH 8.9 buffer and in the second dimension
(chromatography) using a buffer containing n-butanol/pyridine/acetic acid/water (12:10:3:15).
Chromatography was allowed to proceed for 20 h. The amount of
Raf-1 contained in the immunoprecipitates used for the mapping of the
phosphotryptic peptides was determined by immunoblotting an aliquot of
the immunoprecipitates, and it was equal in all samples. Phosphotryptic
peptide mapping was repeated twice with comparable results.
The PP2A Inhibitor Okadaic Acid Decreases Mitogen-induced Raf-1
Activation and Dephosphorylation: Role of Ser259--
We
have studied Raf-1 phosphorylation and activation in BAC-1.2F5
macrophages stimulated by CSF-1 (45, 46). The addition of CSF-1 to
quiescent BAC-1.2F5 cells induced robust and transient activation of
Raf-1 (Fig. 1A; Ref. 45). Peak
(16-fold) Raf-1 activation correlated with the transient
dephosphorylation of serine 621, the main residue phosphorylated in
quiescent macrophages (Fig. 1B, b). Conversely,
the decay of Raf-1 activity to a 4-fold stimulation 15 min post-CSF-1
treatment was accompanied by the hyperphosphorylation of serines 43 and
621. A number of minor yet unidentified residues (spots 2-4) as well
as Ser259 (Fig. 1B, c) were also
phosphorylated at this time. Pretreatment with okadaic acid (100 nM; at this concentration a specific inhibitor of PP2A but
not PP1
To determine whether okadaic acid influenced Raf-1 stimulation by
receptor tyrosine kinases other than the CSF-1 receptor, we analyzed
the effect of the inhibitor on COS-1 cells stimulated with EGF. In
agreement with the data shown in Fig. 1A, okadaic acid
significantly decreased EGF-mediated activation of wild type Raf-1
(Fig. 2A). To assess whether
this effect depended on Ser259, COS-1 cells transfected
with a Ser259
Our data are consistent with the hypothesis that mitogen treatment
induces a kinase that inactivates Raf-1 by phosphorylating Ser259 and is counteracted by an okadaic acid-sensitive
phosphatase. The strength of Raf-1 activation (or the proportion of
Raf-1 molecules that can be activated) would depend on the balance
between the activity of these two enzymes. Such a regulation would be
particularly opportune in the case of Raf-1, whose moderate activation
elicits proliferation, while a strong, prolonged Raf-1 signal leads to cell cycle arrest (48, 49). In line with this hypothesis, while this
manuscript was in preparation, activated protein kinase B was shown to
phosphorylate Ser259 of Raf-1, to suppress the activation
of the mitogen-activated protein kinase cascade, and to shift a cell
line from cell cycle arrest to proliferation (21).
Raf-1 Forms Complexes with PP2A in Vivo and in Vitro--
Okadaic
acid specifically blocked Raf-1 activation at a concentration that
selectively inhibits PP2A (47). We therefore examined whether PP2A
associated physically with Raf-1. Both the catalytic (PP2AC) and the
regulatory (PR65) subunit of the PP2A core enzyme were detected in
Raf-1 immunoprecipitates prepared from quiescent as well as
CSF-1-treated cells. Neither PP2AC nor PR65 could be detected in
precipitates prepared with nonimmune sera (lanes
1 and 2) or with protein A (Fig.
3A). In addition, significant
amounts of Raf-1 were present in immunoprecipitates prepared with a
monoclonal antibody against PP2AC but not with nonimmune mouse IgG
(Fig. 3B), demonstrating the specificity of the interaction.
The ubiquitously expressed PP2A core heterodimer binds to different
variable subunits of cellular or viral origins, which are involved in
regulating its substrate specificity and/or localization. None of the
cellular variable subunits tested (p55
We next verified the interaction between Raf-1 and the PP2A heterodimer
in COS-7 cells transfected with vectors directing the expression of
HA-tagged PP2A subunits (Fig.
4A). Anti-HA
immunoprecipitates from cells transfected with the HA-tagged PP2AC
contained low amounts of endogenous PR65 and Raf-1 (Fig. 4A,
lane 1). Anti-HA immunoprecipitates from cells
transfected with the HA-PR65, on the other hand, contained significant
amounts of endogenous PP2AC subunit and more Raf-1 (Fig. 4A,
compare lanes 1 and 2). Therefore, the
amount of Raf-1 detected correlated with the amount of heterodimer present in the anti-HA immunoprecipitates. To confirm the specificity of the interaction between the HA-tagged PP2A subunits and Raf-1, we
monitored the presence of Raf-1 in anti-HA immunoprecipitates from
cells overexpressing HA-ERK (Fig. 4B). Neither endogenous (lane 3) nor overexpressed Raf-1 (lane
4) could be detected in these immunoprecipitates.
The Raf-1-PP2A complex formation was further analyzed by in
vitro reconstitution experiments with purified proteins (Fig. 4C). GST-tagged Raf was expressed in Sf-9 cells alone or in
combination with v-Ras plus Lck in order to activate it (Raf*). Raf
proteins immobilized on glutathione-Sepharose beads were incubated with PR65, PP2AC, or the heterodimer PR65-PP2AC. Consistent with the lack of
effect of mitogens on in vivo complex formation, we did not
observe significant differences between PP2A binding to Raf or Raf*.
PP2AC displayed only weak binding to Raf-1. In contrast, both PR65 and
the core heterodimer associated strongly. Thus, as it is the case for
cellular and viral subunits (28), PR65 probably plays the key role in
the association between Raf-1 and the PP2A heterodimer. This
association, however, is not likely to be direct. Raf-1 does not
interact with PR65, PP2AC, or p55 in the yeast two-hybrid
system,2 and size
fractionation experiments indicate that in vivo Raf-1 and
PP2A are part of a large protein complex (data not shown). Additional
proteins, and possibly a variable subunit not detected in our
experiments, might also be present in small amounts in the purified
enzyme preparations used in the GST pull-down experiments and might be
facilitating or even mediating the interaction observed in
vitro. In this context, a variable subunit of PP2A has been recently shown to positively regulate Ras signaling upstream of raf during vulval development in Caenorhabditis
elegans (50).
Conclusion--
Concentrations of okadaic acid that specifically
affect PP2A reduced Raf-1 activation, and PP2A was found in Raf-1
immunoprecipitates from quiescent and mitogen-treated cells. Therefore,
while an effect of the drug on other phosphatases cannot be formally
excluded, PP2A presumably represents the okadaic acid-sensitive
phosphatase involved in Raf-1 regulation. Our current working model is
that Raf-1-associated PP2A facilitates kinase activation by maintaining Ser259 in a dephosphorylated state and thereby preventing
the formation of inactive 14-3-3-Raf-1 complexes (14-18). This may
permit the activation of a larger number of Raf-1 molecules and prolong
it by counteracting the mitogen-induced kinase (probably protein kinase
B) that phosphorylates Ser259. Ultimately, the
Ser259 kinase must outpace PP2A to terminate Raf-1
activation. Inhibition of PP2A by okadaic acid has been reported to
selectively impair Raf-dependent transformation (51).
Furthermore, in genetically dissectable organisms, hypomorphic alleles
of PP2A suppress the effects of activated Raf (52) or enhance the loss
of function phenotype of Raf mutations (50). On the basis of these
results, PP2A might have been considered either a Raf-1 effector or a
positive regulator of Raf-1 activation. Our findings provide a
mechanistic explanation for these observations. By identifying PP2A as
a positive regulator of Raf-1, our data define a new function for this
phosphatase and add a new facet to the complexity of Raf-1 regulation.
The skillful technical assistance of Julia
Katzenbeisser is gratefully acknowledged. We thank Dr. Christopher
Marshall (Chester Beatty Laboratories, ICRF, London) for the gift of
bacteria expressing GST-ERK-2 and GST-MEK; Prof. Philip Cohen
(University of Dundee) for the gift of purified recombinant MEK and
mitogen-activated protein kinase; Prof. Jozef Goris, Dr. Patric
Turowski, and Dr. Lisa Ballou for providing purified preparations of
PP2A heterodimer, PR65 *
This work was supported by Austrian Research Fund Grant
P12279-MOB (to M. B.), by European Community Grant PL963328 (to
M. B., B. A. H., and S. M. D.), and by a grant from the Deutsche Forschungsgemeinschaft (Bonn) (to W. K.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
These two authors contributed equally to this work.
§§
To whom correspondence should be addressed. Tel.:
++431-4277-54607; Fax: ++431-4277-9546; E-mail:
manuela@gem.univie.ac.at.
Published, JBC Papers in Press, May 4, 2000, DOI 10.1074/jbc.M003259200
2
J. Rüth, V. Janssens, J. Goris, and M. Baccarini, unpublished observation.
The abbreviations used are:
MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase
kinase;
PP2A, protein phosphatase 2A;
CSF-1, colony-stimulating
factor-1;
HA, hemagglutinin;
CMV, cytomegalovirus;
EGF, epidermal
growth factor;
GST, glutathione S-transferase.
Raf-1-associated Protein Phosphatase 2A as a Positive
Regulator of Kinase Activation*
§,
§,
,
,
,
,
, and
§§
Vienna Biocenter, Institute of Microbiology
and Genetics, Dr. Bohr Gasse 9, A 1030 Vienna, Austria,
¶ Friedrich-Miescher-Institute, Maulbeerstrasse 66, CH 4058 Basel,
Switzerland, the
Department of Metabolic Medicine, Imperial
College School of Medicine, Hammersmith Hospital, Du Cane Road, London
W12 0NN, United Kingdom, the ** Department of Nephrology, Hannover
Medical School, Karl-Neuberg Strasse, D-30625 Hannover, Germany, and

CRC Beatson Laboratories, Garscube Estate,
Switchback Road, Glasgow G61 1BD, United Kingdom
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
(31). Where
investigated (29), PP2A has been shown to contribute to the
inactivation of the associated kinase. Here we show that the PP2A
inhibitor okadaic acid inhibits full fledged Raf-1 activation. This
effect is mediated by a change in the phosphorylation of
Ser259 of Raf-1. In addition, Raf-1 forms stable complexes
with PP2A heterodimers. Our results are the first indication that PP2A
may support the activation of an associated kinase and highlight the intimate relationship between kinases and phosphatases, which we are
just beginning to understand.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
(amino acid 9 to the stop of human PP2AC
cloned downstream of a HA tag in pCMV), PRC/CMV.HA65a (amino acid 3 to
the stop of human PR65a cloned downstream of a HA tag in pRC/CMV),
pCMV-HA-ERK (courtesy of Michael Karin, UCSD), pCMV5Raf-1, and a S259A
Raf-1 mutant (pCMV5-S259A). Cells were harvested 2 days after
transfection. Under these conditions, protein expression increased
linearly between 1 and 10 µg of transfected plasmid DNA. Confluent
cultures were starved for 18 h prior to stimulation with
recombinant CSF-1 (BAC-1.2F5 cells, 6.3 nM mouse
recombinant CSF-1 or 63 nM human recombinant CSF-1 (Chiron
Co.) or EGF (COS-1, 33 nM, 10 min). In selected
experiments, cells were incubated with okadaic acid (100 nM, 45 min) prior to growth factor stimulation.
and PP2AC were immunoprecipitated with the HA-epitope-specific
monoclonal antibody 12CA5. Immunocomplexes were collected following
incubation (1-3 h at 4 °C) with protein A-Sepharose beads (Sigma).
For Western blotting, cell lysates (25 µg/lane) or immunoprecipitates
were separated by 7.5% SDS-PAGE prior to electrophoretic transfer onto Hybond C super (Amersham Pharmacia Biotech). The blots were probed with
rabbit polyclonal antisera directed against Raf-1, PP2AC (antibody
C1-20), PR65
(37), p55
and -
(38), or p72 plus
p130 (39) or with monoclonal antibodies against Raf-1 (PBB.1; Ref. 40),
PP2AC (F2 8F5), or PR 65 (C5 9E10) prior to incubation with horseradish peroxidase-conjugated secondary antibodies and exposure to the ECL
substrate. All blotting reagents were from Amersham Pharmacia Biotech.
The blots were stripped according to the manufacturer's instruction.
) or to activate recombinant MEK-1 in coupled assays
using MBP (41) as the end point of the assay.
, or PP2AC for 3-6 h at 4 °C.
The complexes were recovered by centrifugation and washed in
solubilization buffer containing 0.03% SDS, 10 mM dithiothreitol, 0.5 M NaCl prior to Western blot analysis.
PP2A heterodimer used in this study was provided by Prof. J. Goris (Leuven, Belgium). Catalytic subunit of PP2A was kindly provided by Dr.
Lisa Ballou (I.M.P., Vienna). Both forms of the enzyme were purified
from rabbit skeletal muscle (44). Recombinant PR65
was kindly
provided by Dr. P. Turowski.
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
(47)), caused a slight increase in basal kinase activity
(2-fold) and in Raf-1 phosphorylation in general. Notably, both the
peptide pattern and the amount of activity associated with the Raf-1
immunoprecipitates are identical in cells treated with okadaic acid
alone and in cells treated with CSF-1 for 15 min (Fig. 1, A
and B, compare c and d). This suggests
that both positive and negative regulatory phosphorylation sites are
targets of an okadaic acid-sensitive phosphatase and that the balance between phosphorylation of the positive and negative regulatory sites
determines the extent of Raf-1 activation. Remarkably, in the presence
of okadaic acid, maximal Raf-1 stimulation by CSF-1 was prevented, and
only a moderate (5-6-fold) activation could be obtained. Inhibition of
early serine 621 dephosphorylation and hyperphosphorylation of several
other sites (most prominently serine 259) could be observed
concomitantly. Phosphorylation increased further after 15 min of CSF-1
stimulation; by this time, Raf-1 activation had decayed despite the
continuous presence of the phosphatase inhibitor (Fig. 1, A
and B). Although these changes are complex, it can be
appreciated that Ser259 and Ser621 are less
phosphorylated (hypophosphorylated) in cells treated with CSF-1 alone
than in cells treated with mitogen plus okadaic acid and that this
"hypophosphorylation" correlates with maximal kinase activation.
Thus, an okadaic acid-sensitive phosphatase is involved in Raf-1
dephosphorylation and activation in macrophages.

View larger version (40K):
[in a new window]
Fig. 1.
Dephosphorylation of selected residues
correlates with Raf-1 kinase activation in mitogen-treated
macrophages. A, quiescent BAC-1.2F5 cells were left
untreated (open circles) or were pretreated with
okadaic acid (100 nM, 45 min; closed
squares) prior to stimulation with 6.3 nM CSF-1
for the time periods indicated. The kinase activity of Raf-1
immunoprecipitates was measured in a coupled assay. The results are
expressed as cpm incorporated into the substrate. B,
phosphotryptic peptide maps of Raf-1 immunoprecipitated from
32P-labeled macrophages. The immunoprecipitates in
d-f are from okadaic acid (OA)-pretreated cells.
a and d, quiescent BAC-1.2F5 cells; b
and e, cells stimulated with CSF-1 for 0.5 min; c
and f, cells stimulated with CSF-1 for 15 min prior to cell
lysis and Raf-1 immunoprecipitation. The scheme shows the positions of
Ser43-, Ser259-, and
Ser621-containing peptides, as well as of spot 1 (Ser621 partial digest) and of the unidentified peptides
2-4. Phosphopeptides were identified by co-migration with
corresponding synthetic peptides phosphorylated by PKA in
vitro and by direct comparison with Raf-1 phosphorylation site
mutants expressed in COS-1 cells (not shown). Ser259 shows
a slightly anomalous migration in c. The table
shows the radioactivity in the peptides quantitated using a Fuji
phosphor imager and expressed as arbitrary units. The amount of Raf-1
contained in the immunoprecipitates used for the mapping of the
phosphotryptic peptides was determined by immunoblotting an aliquot of
the immunoprecipitates, and it was equal in all samples. Phosphotryptic
peptide mapping was repeated twice with comparable results.
Ala Raf-1 mutant (RafS259A) were treated
with EGF in the presence or absence of okadaic acid. As described
previously (12, 15, 16, 20, 22), the basal activity of RafS259A was
modestly increased with respect to wild type Raf-1. EGF efficiently
stimulated RafS259A, but in contrast with the wild type, activation of
RafS259A was not decreased by pretreatment with okadaic acid (Fig.
2B). These data confirm the importance of the okadaic
acid-sensitive phosphatase in Raf-1 activation by receptor tyrosine
kinases and identify Ser259 as the Raf-1 site relevant for
activation. The effect of okadaic acid on the activation of wild type
Raf-1 in EGF-treated COS-1 cells was less dramatic than the one
observed in BAC-1.2F5 macrophages stimulated by CSF-1. It is possible
that the importance of dephosphorylation in Raf-1 activation may vary
depending on the cell type; alternatively, Raf-1 overexpression might
adversely affect the outcome of the experiment, as is often the case
when multienzyme complexes are involved (see below).

View larger version (29K):
[in a new window]
Fig. 2.
EGF-stimulated activation of wild type Raf-1,
but not of a S259A Raf-1 mutant, is decreased by okadaic acid in COS-1
cells. COS-1 cells were transfected with a vector encoding human
wild type Raf-1 (pCMV5c-raf) or S259A Raf-1 mutant
(pCMV5-S259A). 48 h after transfection, cells were treated with
okadaic acid (100 nM, 45 min) prior to stimulation with EGF
(33 nM, 10 min), lysis, and immunoprecipitation. Raf-1
immunoprecipitates (duplicates) were assayed for kinase activity in a
coupled assay. The amount of Raf-1 in the immune complexes was
determined by immunoblotting. One representative kinase assay out of
three is shown. Differences between samples were below 5% in all
cases.
and -
, and p72 plus p130)
was present in Raf-1 immunoprecipitates (not shown). Consistent
findings were obtained in fibroblasts stimulated with EGF (not
shown).

View larger version (24K):
[in a new window]
Fig. 3.
Endogenous Raf-1 interacts with PP2A
heterodimers in vivo. A, the PP2A core
heterodimer is present in Raf-1 immunoprecipitates from quiescent and
mitogen-stimulated BAC-1.2F5 cells. Quiescent BAC-1.2F5 cells were
stimulated with 6.3 nM mouse recombinant CSF-1 at 37 °C
for different times prior to solubilization. Raf-1 immunoprecipitates
from 1 mg of whole cell lysates were analyzed by Western blotting with
antisera directed against the 36-kDa catalytic subunit of PP2A,
PR65
, and Raf-1. 25 µg of whole cell lysates (WCL) were
loaded as a control. Neither PP2AC nor PR65 were detected in
immunoprecipitates prepared using nonimmune rabbit sera (NI)
or protein A beads (A) instead of the Raf-1-specific
antiserum. The background bands observed in the PP2AC Westerns could
also be detected by anti-rabbit antibody alone and represent IgG heavy
chains. B, Raf-1 is present in PP2AC immunoprecipitates.
BAC-1.2F5 were solubilized, and 1 mg of whole cell lysates were
subjected to immunoprecipitation using a monoclonal antibody against
PP2AC (PP2AC), nonimmune mouse IgG (NI), or an
anti-Raf-1 serum. The immunoprecipitates were analyzed with monoclonal
antibodies directed against PP2AC, PR65, or Raf-1.

View larger version (16K):
[in a new window]
Fig. 4.
PP2A subunits interact with Raf-1 in
transfected COS cells and in vitro. A,
Raf-1/PP2A interaction in transiently transfected COS cells. COS-7
cells were transfected by electroporation with plasmids encoding
HA-tagged human PP2AC
, HA-tagged human PR65
, or empty vector. Two
days after transfection, the cells were harvested and the HA-tagged
subunits of the PP2A heterodimer were immunoprecipitated with an
anti-HA antibody. The immunoprecipitates were analyzed by Western
blotting with antisera directed against Raf-1, PR65, the 36-kDa
catalytic subunit of PP2A (PP2AC), or the HA tag (HA-PR65 and
HA-PP2AC). B, lack of Raf-1 interaction with HA-ERK. COS-7
cells were transfected by electroporation with plasmids encoding
HA-tagged ERK (pCMV-HA-ERK2) and empty vector or wild type Raf-1. HA or
Raf-1 immunoprecipitates were analyzed by Western blotting with
antisera directed against Raf-1 or the HA-tag. C, binding of
purified PP2A heterodimers, PP2AC, and PR65 to Raf-1 and Raf-1*
in vitro. GST (200 ng), GST-Raf-1 (200 ng), and GST-Raf-1*
(Raf-1 activated by co-infection of Sf9 cells with baculoviruses
encoding v-ras and lck; 100 ng) were immobilized
on glutathione-agarose beads and incubated for 3 h at 4 °C with
200 ng of purified core heterodimer (D), PP2AC
(C), or recombinant PR65 (R). Complexes were
recovered by centrifugation and washed in a buffer containing 0.03%
SDS, 0.5 M NaCl prior to electrophoresis and Western blot
analysis. 20 ng of purified dimer (D) and PP2AC plus PR65
(C+R) were loaded as a control.
![]()
ACKNOWLEDGEMENTS
, and PP2AC, respectively; and Dr. Jolanda
Schreurs (Chiron Corp. Emeryville, CA) for supplying human recombinant
CSF-1. We are indebted to Drs. Egon Ogris and Thomas Decker (Vienna
Biocenter) for many helpful discussions and for critically reading the manuscript.
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
1.
Monia, B. P.,
Johnston, J. F.,
Geiger, T.,
Muller, M.,
and Fabbro, D.
(1996)
Nat. Med.
2,
668-675
2.
Daum, G.,
Eisenmann-Tappe, I.,
Fries, H. W.,
Troppmair, J.,
and Rapp, U. R.
(1994)
Trends Biochem. Sci.
19,
474-480
3.
Marshall, M.
(1995)
Mol. Reprod. Dev.
42,
493-499
4.
McCormick, F.
(1995)
Mol. Reprod. Dev.
42,
500-506
5.
Diaz, B.,
Barnard, D.,
Filson, A.,
MacDonald, S.,
King, A.,
and Marshall, M.
(1997)
Mol. Cell. Biol.
17,
4509-4516
6.
King, A. J.,
Sun, H.,
Diaz, B.,
Barnard, D.,
Miao, W.,
Bagrodia, S.,
and Marshall, M. S.
(1998)
Nature
396,
180-183
7.
Marais, R.,
Light, Y.,
Paterson, H. F.,
and Marshall, C. J.
(1995)
EMBO J.
14,
3136-3145
8.
Mason, C. S.,
Springer, C. J.,
Cooper, R. G.,
Superti-Furga, G.,
Marshall, C. J.,
and Marais, R.
(1999)
EMBO J.
18,
2137-2148
9.
Wartmann, M.,
and Davis, R. J.
(1994)
J. Biol. Chem.
269,
6695-6701
10.
Wartmann, M.,
Hofer, P.,
Turowski, P.,
Saltiel, A. R.,
and Hynes, N. E.
(1997)
J. Biol. Chem.
272,
3915-3923
11.
Alessi, D. R.,
Cuenda, A.,
Cohen, P.,
Dudley, D. T.,
and Saltiel, A. R.
(1995)
J. Biol. Chem.
270,
27489-27494
12.
Morrison, D. K.,
Heidecker, G.,
Rapp, U. R.,
and Copeland, T. D.
(1993)
J. Biol. Chem.
268,
17309-17316
13.
Muslin, A. J.,
Tanner, J. W.,
Allen, P. M.,
and Shaw, A. S.
(1996)
Cell
84,
889-897
14.
Aitken, A.
(1996)
Trends Cell Biol.
6,
341-347
15.
Rommel, C.,
Radziwill, G.,
Moelling, K.,
and Hafen, E.
(1997)
Mech. Dev.
64,
95-104
16.
Tzivion, G.,
Luo, Z.,
and Avruch, J.
(1998)
Nature
394,
88-92
17.
Roy, S.,
McPherson, R. A.,
Apolloni, A.,
Yan, J.,
Lane, A.,
Clyde-Smith, J.,
and Hancock, J. F.
(1998)
Mol. Cell. Biol.
18,
3947-3955
18.
Thorson, J. A., Yu, L. W.,
Hsu, A. L.,
Shih, N. Y.,
Graves, P. R.,
Tanner, J. W.,
Allen, P. M.,
Piwnica-Worms, H.,
and Shaw, A. S.
(1998)
Mol. Cell. Biol.
18,
5229-5238
19.
Mischak, H.,
Seitz, T.,
Janosch, P.,
Eulitz, M.,
Steen, H.,
Schellerer, M.,
Philipp, A.,
and Kolch, W.
(1996)
Mol. Cell. Biol.
16,
5409-5418
20.
Baek, K. H.,
Fabian, J. R.,
Sprenger, F.,
Morrison, D. K.,
and Ambrosio, L.
(1996)
Dev. Biol.
175,
191-204
21.
Zimmermann, S.,
and Moelling, K.
(1999)
Science
286,
1741-1744
22.
Michaud, N. R.,
Fabian, J. R.,
Mathes, K. D.,
and Morrison, D. K.
(1995)
Mol. Cell. Biol.
15,
3390-3397
23.
Wera, S.,
and Hemmings, B. A.
(1995)
Biochem. J.
311,
17-29
24.
Pallas, D. C.,
Shahrik, L. K.,
Martin, B. L.,
Jaspers, S.,
Miller, T. B.,
Brautigan, D. L.,
and Roberts, T. M.
(1990)
Cell
60,
167-176
25.
Yang, S. I.,
Lickteig, R. L.,
Estes, R.,
Rundell, K.,
Walter, G.,
and Mumby, M. C.
(1991)
Mol. Cell. Biol.
11,
1988-1995
26.
Sontag, E.,
Fedorov, S.,
Kamibayashi, C.,
Robbins, D.,
Cobb, M.,
and Mumby, M.
(1993)
Cell
75,
887-897
27.
Ruediger, R.,
Roeckel, D.,
Fait, J.,
Bergqvist, A.,
Magnusson, G.,
and Walter, G.
(1992)
Mol. Cell. Biol.
12,
4872-4882
28.
Kamibayashi, C.,
and Mumby, M. C.
(1995)
Adv. Protein Phosphatases
9,
195-210
29.
Westphal, R. S.,
Anderson, K. A.,
Means, A. R.,
and Wadzinski, B. E.
(1998)
Science
280,
1258-1261
30.
Westphal, R. S.,
Coffee, R. L., Jr.,
Marotta, A.,
Pelech, S. L.,
and Wadzinski, B. E.
(1999)
J. Biol. Chem.
274,
687-692
31.
Heriche, J. K.,
Lebrin, F.,
Rabilloud, T.,
Leroy, D.,
Chambaz, E. M.,
and Goldberg, Y.
(1997)
Science
276,
952-955
32.
Morgan, C.,
Pollard, J. W.,
and Stanley, E. R.
(1987)
J. Cell. Physiol.
130,
420-427
33.
Stanley, E. R.
(1985)
Methods Enzymol.
116,
564-587
34.
Dilworth, S. M.,
and Horner, V. P.
(1993)
J. Virol.
67,
2235-2244
35.
Evans, D. R.,
Myles, T.,
Hofsteenge, J.,
and Hemmings, B. A.
(1999)
J. Biol. Chem.
274,
24038-24046
36.
Baccarini, M.,
Li, W.,
Sbarba, P. D.,
and Stanley, E. R.
(1991)
Receptor
1,
243-259
37.
Turowski, P.,
Fernandez, A.,
Favre, B.,
Lamb, N. J.,
and Hemmings, B. A.
(1995)
J. Cell Biol.
129,
397-410
38.
Hendrix, P.,
Turowski, P.,
Mayer-Jaekel, R. E.,
Goris, J.,
Hofsteenge, J.,
Merlevede, W.,
and Hemmings, B. A.
(1993)
J. Biol. Chem.
268,
7330-7337
39.
Hendrix, P.,
Mayer-Jackel, R. E.,
Cron, P.,
Goris, J.,
Hofsteenge, J.,
Merlevede, W.,
and Hemmings, B. A.
(1993)
J. Biol. Chem.
268,
15267-15276
40.
Kolch, W.,
Weissinger, E.,
Mischak, H.,
Troppmair, J.,
Showalter, S. D.,
Lloyd, P.,
Heidecker, G.,
and Rapp, U. R.
(1990)
Oncogene
5,
713-720
41.
Alessi, D. R.,
Cohen, P.,
Ashworth, A.,
Cowley, S.,
Leevers, S. J.,
and Marshall, C. J.
(1995)
Methods Enzymol.
255,
279-290
42.
Li, S.,
Janosch, P.,
Tanji, M.,
Rosenfeld, G. C.,
Waymire, J. C.,
Mischak, H.,
Kolch, W.,
and Sedivy, J. M.
(1995)
EMBO J.
14,
685-696
43.
Macdonald, S. G.,
Crews, C. M.,
Wu, L.,
Driller, J.,
Clark, R.,
Erikson, R. L.,
and McCormick, F.
(1993)
Mol. Cell. Biol.
13,
6615-6620
44.
Stone, S. R.,
Hofsteenge, J.,
and Hemmings, B. A.
(1987)
Biochemistry
26,
7215-7220
45.
Buscher, D.,
Hipskind, R. A.,
Krautwald, S.,
Reimann, T.,
and Baccarini, M.
(1995)
Mol. Cell. Biol.
15,
466-475
46.
Krautwald, S.,
Buscher, D.,
Kummer, V.,
Buder, S.,
and Baccarini, M.
(1996)
Mol. Cell. Biol.
16,
5955-5963
47.
Favre, B.,
Turowski, P.,
and Hemmings, B. A.
(1997)
J. Biol. Chem.
272,
13856-13863
48.
Sewing, A.,
Wiseman, B.,
Lloyd, A. C.,
and Land, H.
(1997)
Mol. Cell. Biol.
17,
5588-5597
49.
Woods, D.,
Parry, D.,
Cherwinski, H.,
Bosch, E.,
Lees, E.,
and McMahon, M.
(1997)
Mol. Cell. Biol.
17,
5598-5611
50.
Sieburth, D. S.,
Sundaram, M.,
Howard, R. M.,
and Han, M.
(1999)
Genes Dev.
13,
2562-2569
51.
Sakai, R.,
Ikeda, I.,
Kitani, H.,
Fujiki, H.,
Takaku, F.,
Rapp, U.,
Sugimura, T.,
and Nagao, M.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
9946-9950
52.
Wassarman, D. A.,
Solomon, N. M.,
Chang, H. C.,
Karim, F. D.,
Therrien, M.,
and Rubin, G. M.
(1996)
Genes Dev.
10,
272-278
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
M. Zang, J. Gong, L. Luo, J. Zhou, X. Xiang, W. Huang, Q. Huang, X. Luo, M. Olbrot, Y. Peng, et al. Characterization of Ser338 Phosphorylation for Raf-1 Activation J. Biol. Chem., November 14, 2008; 283(46): 31429 - 31437. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Thiaville, Y.-X. Pan, A. Gjymishka, C. Zhong, R. J. Kaufman, and M. S. Kilberg MEK Signaling Is Required for Phosphorylation of eIF2{alpha} following Amino Acid Limitation of HepG2 Human Hepatoma Cells J. Biol. Chem., April 18, 2008; 283(16): 10848 - 10857. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Junttila, S.-P. Li, and J. Westermarck Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival FASEB J, April 1, 2008; 22(4): 954 - 965. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. C. Harwood, L. Shu, and P. J. Houghton mTORC1 Signaling Can Regulate Growth Factor Activation of p44/42 Mitogen-activated Protein Kinases through Protein Phosphatase 2A J. Biol. Chem., February 1, 2008; 283(5): 2575 - 2585. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Adler, W. Bowne, J. Michl, K. A. Sookraj, K. Ikram, S. Pestka, L. Izotova, M. Zenilman, F. K. Friedman, Y. Qu, et al. Site-Specific Phosphorylation of raf in Cells Containing Oncogenic ras-p21 Is Likely Mediated by jun-N-Terminal Kinase Ann. Clin. Lab. Sci., January 1, 2008; 38(1): 47 - 56. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. von Bulow, S. Dubben, G. Engelhardt, S. Hebel, B. Plumakers, H. Heine, L. Rink, and H. Haase Zinc-Dependent Suppression of TNF-{alpha} Production Is Mediated by Protein Kinase A-Induced Inhibition of Raf-1, I{kappa}B Kinase beta, and NF-{kappa}B J. Immunol., September 15, 2007; 179(6): 4180 - 4186. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Nazarenko, R. Schafer, and C. Sers Mechanisms of the HRSL3 tumor suppressor function in ovarian carcinoma cells J. Cell Sci., April 15, 2007; 120(8): 1393 - 1404. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Sun, G. Stoecklin, S. Van Way, V. Hinkovska-Galcheva, R.-F. Guo, P. Anderson, and T. P. Shanley Tristetraprolin (TTP)-14-3-3 Complex Formation Protects TTP from Dephosphorylation by Protein Phosphatase 2a and Stabilizes Tumor Necrosis Factor-{alpha} mRNA J. Biol. Chem., February 9, 2007; 282(6): 3766 - 3777. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Hmitou, S. Druillennec, A. Valluet, C. Peyssonnaux, and A. Eychene Differential Regulation of B-Raf Isoforms by Phosphorylation and Autoinhibitory Mechanisms Mol. Cell. Biol., January 1, 2007; 27(1): 31 - 43. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Y. C. Chow and K. E. Barrett Role of protein phosphatase 2A in calcium-dependent chloride secretion by human colonic epithelial cells Am J Physiol Cell Physiol, January 1, 2007; 292(1): C452 - C459. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Rodriguez-Viciana, C. Collins, and M. Fried Polyoma and SV40 proteins differentially regulate PP2A to activate distinct cellular signaling pathways involved in growth control PNAS, December 19, 2006; 103(51): 19290 - 19295. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-H. Lee, J.-S. Lee, S.-E. Kim, B.-S. Moon, Y.-C. Kim, S.-K. Lee, S.-K. Lee, and K.-Y. Choi Tautomycetin inhibits growth of colorectal cancer cells through p21cip/WAF1 induction via the extracellular signal-regulated kinase pathway Mol. Cancer Ther., December 1, 2006; 5(12): 3222 - 3231. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. G. Ossum, T. Wulff, and E. K. Hoffmann Regulation of the mitogen-activated protein kinase p44 ERK activity during anoxia/recovery in rainbow trout hypodermal fibroblasts J. Exp. Biol., May 1, 2006; 209(9): 1765 - 1776. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-Z. Tao, D. M. Toivola, Q. Zhou, P. Strnad, B. Xu, S. A. Michie, and M. B. Omary Protein phosphatase-2A associates with and dephosphorylates keratin 8 after hyposmotic stress in a site- and cell-specific manner. J. Cell Sci., April 1, 2006; 119(Pt 7): 1425 - 1432. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. K. Rushworth, A. D. Hindley, E. O'Neill, and W. Kolch Regulation and role of raf-1/b-raf heterodimerization. Mol. Cell. Biol., March 1, 2006; 26(6): 2262 - 2272. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Balan, D. T. Leicht, J. Zhu, K. Balan, A. Kaplun, V. Singh-Gupta, J. Qin, H. Ruan, M. J. Comb, and G. Tzivion Identification of Novel In Vivo Raf-1 Phosphorylation Sites Mediating Positive Feedback Raf-1 Regulation by Extracellular Signal-regulated Kinase Mol. Biol. Cell, March 1, 2006; 17(3): 1141 - 1153. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Adams, R. L. Coffee Jr., H. Zhang, S. Pelech, S. Strack, and B. E. Wadzinski Positive Regulation of Raf1-MEK1/2-ERK1/2 Signaling by Protein Serine/Threonine Phosphatase 2A Holoenzymes J. Biol. Chem., December 30, 2005; 280(52): 42644 - 42654. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Konopleva, Y. Shi, L. S. Steelman, J. G. Shelton, M. Munsell, F. Marini, T. McQueen, R. Contractor, J. A. McCubrey, and M. Andreeff Development of a Conditional In vivo Model to Evaluate the Efficacy of Small Molecule Inhibitors for the Treatment of Raf-Transformed Hematopoietic Cells Cancer Res., November 1, 2005; 65(21): 9962 - 9970. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Van Kanegan, D. G. Adams, B. E. Wadzinski, and S. Strack Distinct Protein Phosphatase 2A Heterotrimers Modulate Growth Factor Signaling to Extracellular Signal-regulated Kinases and Akt J. Biol. Chem., October 28, 2005; 280(43): 36029 - 36036. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ziogas, K. Moelling, and G. Radziwill CNK1 Is a Scaffold Protein That Regulates Src-mediated Raf-1 Activation J. Biol. Chem., June 24, 2005; 280(25): 24205 - 24211. [Abstract] [Full Text] [PDF] |
||||
![]() |
|